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Abstract The opportunity to undergo an induced pluripotent
stem cell-based autologous transplant can strike patients as a
chance for a cure from a debilitating condition with few
options for respite. However, when clinical studies of this
caliber present themselves, patients and researchers, each with
their own set of motives, may find it difficult to take a
balanced approach to evaluating them. We present a patient-
centered risk-benefit analysis of the iPSC-based clinical re-
search currently underway in Japan, including a survey of
in vitro and in vivo tests that support this project, an in-
depth discussion of risks, and further elucidation of consider-
ations patients may wish to consider. The arguments presented
will assist patients in undertaking a more informed decision-
making process.
Keywords Human subject research . Induced pluripotent
stem cells (iPSCs) . Age-related macular degeneration
(AMD) . Patient-centered risk-benefit analysis .
Tumorigenicity . Therapeutic misconception/misestimation
Abbreviations
iPSC induced pluripotent stem cells
hESC human embryonic stem cells
AMD age-related macular degeneration
RPE retinal pigmental epithelium
CNV choroidal neovascularization
Introduction
The launch of the world’s first pilot clinical research to use
patient-derived iPSCs for retinal regeneration was officially
announced in Japan on July 30, 2013 [1]. This study, which is
currently recruiting six patients over the next two to 3 years,
targets age-related macular degeneration (AMD) in the exu-
dative form, commonly called wet AMD [2]. Wet AMD is a
degenerative retinal disease in which abnormal blood vessels
(choroidal neovascularization, CNV) develop in the macula,
the region in the back center of the eyeball. This CNV invades
retinal pigmental epithelium (RPE) that nourishes and sup-
ports photoreceptors, and thereby causes loss of central vision.
The idea of the pilot study is to surgically replace the damaged
RPE cells with healthy cells developed from patient-derived
iPSCs. Researchers will take skin tissue samples (4 mm di-
ameter) from a consenting patient’s upper arm, induce those
skin cells into iPSCs by exogenously expressing key
pluripotency genes, create sheets of RPE from iPSCs (with
the processing time of approx.10 months), cut the RPE sheets
into appropriate size (dose not specified) and transplant them
under retina after removing CNV under general anesthesia
(Fig. 1). The researchers will then investigate possible im-
mune rejection or tumor formation caused by the transplant
and other adverse effects and problems during the one-year
postoperative period (every month for the first half a year and
every 2 months thereafter), with additional 3 years of follow-
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up. The prospective subjects must be age 50 or over, with
refractory or recurrent wet AMD in at least one eye with the
corrected visual acuity worse than 20/67 (0.3 in decimals).
With this approach, researchers hope to halt retinal degenera-
tion in patients with AMD, though safety evaluation, not
therapeutic efficacy, of this autologous transplant is the pri-
mary focus of the study. Therefore, this study is labeled as a
pilot clinical study (rinsho kenkyu) instead of a clinical trial
that explicitly intends to develop a therapeutic product.
Since Japan’s pilot study is the first iPSC-based autologous
transplant on human subjects, its ethical framework will set a
precedent for subsequent iPSC-based transplants. Before
iPSC-based cell therapy comes into wider clinical use, risk-
benefit analyses, informed consent procedures, and ethical
review and monitoring processes need to be carefully exam-
ined. Although Japan’s iPSC clinical research is not the first
attempt to develop stem cell therapy for retinal diseases, as
there have already been human clinical trials to transplant
hESC- or fetal cell- derived retinal cells for macular degener-
ation [3, 4], we emphasize the importance of discussing the
ethics of iPSC-based clinical research as a separate issue from
ethics of hESC-based clinical trials. When compared with
hESCs and other cell-based therapy, the iPSCs created from
patients’ skin tissues are believed to be genetically identical to
each patient’s cells, which could reduce the risk of immune
rejection of the transplanted graft by recipient. This may
suggest that iPSC-based cell therapy could be a feasible
alternative to former transplant attempts. Furthermore, the
use of iPSCs is commonly regarded as “more ethical” than
the use of hESCs or other embryo-derived cells because the
establishment of iPSCs does not involve the use of early
human embryos. These two promising features of iPSCs,
together with the fact that Dr. Shinya Yamanaka from Japan
received the Nobel Prize in 2012 for the successful establish-
ment of iPSCs, excite the Japanese community enough to
welcome virtually any ideas of iPSC-based clinical studies.
However, it is well documented that there are additional safety
and ethical concerns peculiar to clinical applications of iPSCs,
as will be discussed later. Researchers must be able to clearly
explain such potential concerns to research subjects who are
also patients. The ethical challenges of the Japan’s first-in-
human iPSC clinical study have been concisely discussed by
Habets et al. [5]. Instead of discussing the social value of the
clinical study as these authors did, the present paper will focus
on the direct risks and benefits to participating patients in
order to examine whether these patients could be exploited
for the sake of the research’s social value. In addition, Habets
et al. do not describe the efforts that the Japanese investigators
have made to reduce the study-associated risks. We will
appreciate such efforts yet claim that there remains a gap
between patients’ and researchers’ perceptions of favorable
risk-benefit ratios. The ultimate goal of this paper is not to hail
or to denounce this type of research, but to enable the re-
searchers to help their patients make informed choices.
Patient-Centered Risk Benefit Analysis
An important concept to remember when we conduct such a
patient-centered analysis is that the patients’ standpoint is
Fig. 1 Scheme describing the
flow of how iPSCs are generated
from a patient’s skin cells and
differentiated into RPE cells to be
transplanted into the eye of the
AMD patient
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fundamentally different from the researchers’ standpoint. Sub-
sequently, the term “risk-benefit analysis” has a dual meaning
depending on which perspective is taken. Though there have
been intensive discussions in the field of bioethics on whether
we should keep drawing a sharp line between clinical research
and clinical practice [6], the Belmont Report’s clear statement
that research is an activity quite distinct from clinical practice
[7] is still significant and relevant for the purpose of protecting
human subjects. The goal of clinical practice is to benefit
particular patients by providing the best available treatment
and care, whereas the goal of clinical research is to produce
generalizable knowledge that may hopefully contribute to
future medicine. Given this difference in perceived goals, it
is natural for a patient to expect from what he perceives as “an
experimental treatment” certain therapeutic benefits, even if
that “treatment” is actually research conducted in a clinical
setting – this phenomenon is widely known as therapeutic
misconception [8]. Additionally, the notion of a favorable
risk-benefit ratio, as perceived by researchers, might be dif-
ferent from that of patients, which leads to another phenom-
enon called therapeutic misestimation, or a patient’s tendency
to underestimate risks and overestimate benefits of the re-
search. Researchers may think that minor risks to a few
patients would be outweighed by possible greater therapeutic
benefits to numerous future patients. By contrast, a patient
may think that minor risks to one’s health would be
outweighed only by possible greater benefits to oneself, not
others. Furthermore, when a patient is considering whether to
participate in a clinical trial or research, what he or she
considers would not only be the comparison between the
benefits and harms resulting from participating in research
(as shown in Fig. 2a) but also the comparison between alter-
native options, each of which involves its own set of advan-
tages and disadvantages (Fig. 2b). We should keep in mind
that Fig. 2a merely covers the comparison between 1) and 2)
in Fig. 2b. To conclude that a certain research is expected to
bring about a positive surplus of benefits over risks is not to
conclude that this surplus outweighs another surplus of bene-
fits over risks of not participating in that research. Even if the
proposed research’s therapeutic benefits to millions of other
patients appear to outweigh relatively small research risks to
you, you will have no reason, except for altruistic reasons, to
prefer research over non-participation when non-participation
is expected to bring you greater overall surplus of benefits
over risks than the overall surplus of benefits over risks that
the research is expected to bring to you.
This discrepancy between the two parties’ perspectives
becomes visible when we take a careful look at how re-
searchers explain their research project to potential partici-
pants during the informed consent process. The informed
consent document prepared by the Japan’s iPSC-based
AMD research group [9] provides a detailed explanation
about their research project, covering most items that every
human subject research is supposed to cover. It explains who
qualifies as research subject, length and duration of the study,
the experimental nature and purpose of the study, caution
about expected benefits, risks and inconveniences associated
with the study, the freedom to withdraw one’s consent at any
time without jeopardy, as well as other procedural directions
about how to participate in the study. These are items that are
commonly mandated by standard informed consent guide-
lines, such as the Declaration of Helsinki [10] and the Japan
Ministry of Health, Labor and Welfare’s Ethical Guideline for
Clinical Studies [11]. The same informed consent document
also mentions, at least to a moderate extent, the novelty and
unpredictability of early iPSC-based clinical study, the tumor-
igenicity risks of iPSCs as well as the researchers’ plan to
compensate research-related health damages, in line with the
recommendations set forth in the International Society for
Stem Cell Research (ISSCR)’s Guidelines for the Clinical
Fig. 2 Two Sets of Comparisons. (A) A limited comparison of risks and benefits, as compared to (B) patient-centered decision-making process
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Translation of Stem Cells [12, 13]. However, the researchers’
description of the study does not fully explain several factors
that could sway patients’ decisions, and as it stands, it could
possibly encourage patients and their families to maintain
their therapeutic misestimation. First, the informed consent
document would give readers the impression that not all, but
most safety concerns are now cleared and that the research is
expected to give mild yet positive enough benefits to call the
experimental procedure a therapy. It could alarm patients by
listing over twenty kinds of possible adverse events that may
possibly result from skin tissue sampling, general anesthesia,
retinal surgery and iPSC-derived RPE transplant. However,
many of such risks seem to be always described in any consent
documents for clinical trials. Among the long list of adverse
events, one may notice the description about the possibility of
tumor formation, or tumorigenicity, of the transplanted cells.
Here the informed consent document points out that it is
impossible to rule out the risk of tumor formation triggered
by the transplanted RPE sheet, since iPSCs, which have the
capacity to proliferate indefinitely, are known to form tumors
if they are directly transplanted into the body of a living
organism. However, the same document continues to argue
that there was not even a single case of tumor formation in
their preclinical animal studies of iPSC-derived RPE trans-
plant. In another place of the document, it is also explained
that the original method to create iPSCs using retroviruses had
a high chance of causing abnormalities including tumors, but
that such a method is now replaced by a new method using
what is called a plasmid, which significantly reduced the
tumorigenicity risks of iPSCs. Such explanations will give
patients the impression that the investigators’ current method
is safe enough. Patients may further be relieved to read the
researchers’ assurance that the doctors will carefully monitor
all risks and, should any adverse event occur, provide the
standard therapy for it. As for the potential benefits of the
research, the informed consent document describes that
“this study . . . is not expected to bring about remarkable
therapeutic effects such as dramatic improvements in vi-
sual acuity,” but adds that “the subretinal new blood
vessels and exudates will disappear after therapy” and
that “it is expected that the retina adjacent to the
transplanted new RPE cells will rejuvenate, which would
result in the improved brightness in the central vision,
prevention of further visual deterioration and, in some
cases, slight improvement in visual acuity.” Without un-
derstanding how probable those benefits are, and which
evidence supports such expectations, patients and their
families may have the impression that this research in-
volves mild yet positive effects. Patients could reason,
quite legitimately, that this research is most likely to be
effective – for, if little therapeutic benefits are expected,
what is the point of conducting this study? The autolo-
gous feature of this transplant study may make patients
optimistic as well – they may well believe that, if their
own cells will be used and “put back into them,” it cannot
be entirely dangerous.
Second, the RIKEN’s informed consent document explains
the risks and benefits of the iPSC-based RPE transplant study
in comparison with existing standard therapies, suggesting
that none of them are truly effective so far. Given such
information alone, patients and their families could believe
that iPSC-based RPE transplant is the only promising therapy
currently available. However, patients need to examine further
the information about all options available to them, not limited
to current standard therapies, but also information about other
emerging non-standard therapies and ongoing clinical trials,
and more detailed information of non-treatment options. Pro-
spective subjects, who are also patients, need to consider what
the life with the disease will look like, and whether the life
with current standard therapy or the life without any treatment
will be so miserable that they desperately need to try any new
therapy whenever possible.
Third, researchers may tend to assume that a patient is fully
informed and is content with the information given to them
when the patient asks no questions. In reality, patients may ask
few or no questions because they made a bet – simply because
they hold onto their therapeutic misestimation based on the
limited amount of information given to them.
This is not a researchers’ fault, as the informed consent
procedure conforms to major ethical guidelines, and the en-
deavor to develop safe and effective treatments is a highly
regarded mission of clinical scientists. In the following sec-
tions, we will make a supplemental endeavor to help re-
searchers (and referring physicians) provide patients with
further information on the safety, efficacy and necessity of
the proposed pilot study in an attempt to help avoid patients’
therapeutic misestimation and to alleviate miscommunication
between researchers and patients.
Is Science Behind Risks Understood?
Any clinical research involves certain risks. For patients, risks
associated with participation in clinical research are worth
taking when (1) they can expect that those risks are minor
and ignorable and they are convinced that they can contribute
to the advancement of medicine with this minor sacrifice of
themselves; or when (2) they can expect greater therapeutic
benefits that compensate research-associated risks and this
surplus of benefits over risks is greater than that of other
courses of actions they could take.
One feature of the approved iPSC-RPE transplant pilot
study is that it is uncertain whether the research-associated
risks are truly minor and ignorable. In fact, this is precisely the
reason why the primary focus of Japan’s pilot study is the
safety of the transplant.
746 Stem Cell Rev and Rep (2014) 10:743–752
Researchers’ main safety concern is tumorigenicity, or the
risk of tumor development, of the iPSCs and the iPSC-derived
transplanted grafts [14]. First, “pluripotency,” the potential of
iPSCs to differentiate into any type of cells that consist our
body, is the hallmark of tumor initiating cells. Similar to ES
cells, iPSCs are capable of forming tumors when those cells
are injected as immature state into immunocompromised
mice. Therefore, if the iPSC-derived grafts contained incom-
pletely differentiated cells, those cells would have the tumor-
igenic potential. Most of such tumors are benign teratomas,
but there are reported cases of malignant germ-cell tumors,
such as embryonal carcinoma, being formed [15, 16]. Second,
even differentiated pluripotent stem cells could reprogram
their cell fate, resulting in de-differentiation into tumorigenic
potential, for they may retain or reactivate once-activated yet
artificially silenced pluripotency-gene expression pathways
inherent to them [14, 17]. Cell-culture-induced differentiation
occurs through multiple mechanisms, many of which are
epigenetic events, and a majority, if not all, of epigenetic
events are reversible. It is true that during the course of
differentiation, these cells supposedly lose the capacity to re-
acquire the immature stem cell state, but we have to be careful
as to whether the cells for clinical use, which should have
“differentiated” via in vitro cell culture, indeed commit to
irreversible differentiation. Due to the limited studies on this
potential dedifferentiation mechanism, the chance of
reprogramming event of the differentiated iPS cells into tu-
morigenic potential remains unknown. Given that the native
somatic cells have some risks to become cancers, the open
question is whether the cancer-initiating risk of injected “de-
differentiated” iPSCs is reasonably lower than the cancer-
initiating risks of the native somatic cells.
Another concern with the use of iPSCs is their genomic
instability, due to its artificial cell reprogramming process,
which may lead to even higher risks of generating tumors
than ESCs [18]. In particular, the classic method to produce
iPSCs involves the insertion of pluripotency genes (including
oncogenic c-Myc) via viral vectors. The use of retroviral
vectors allows the integration of pluripotency-initiating genes
into the host genome, which may cause mutations in the host
cells, or the inserted genes may reactivate the pluripotency
network even after the host cell undergoes differentiation. In
addition, previous studies have demonstrated the deletion of a
number of tumor-suppressor genes in established iPSCs
(while those genes were present in the somatic cells of origin),
which directly indicates chromosomal instability with de novo
mutations for tumorigenesis in iPSCs [19].
Researchers have made several attempts to prevent these
tumorigenicity-associated risks. They circumvent genome-
integrative reprogramming methods by causing only transient
expression of pluripotency factors to initialize somatic cells,
the effect of which gradually gets lost once the iPSCs are
established and start replicating themselves [20]. Such non-
integrative reprogramming methods include the use of epi-
somal vectors (containing round-shaped DNAs called plas-
mids that replicate themselves) [21], Sendai virus (a minus
strand RNA virus that can infect the somatic cells for a
relatively long time) [22], and the use of a synthetic self-
replicative RNAs [23] or small molecule compounds alone
[24]. Researchers also substitute oncogenic pluripotency
genes with different genes that have not been previously
known to be involved in tumorigenesis [21, 25]. More recent-
ly reported was a simpler method of reprogramming somatic
cells into iPSC-like cells by exposing the cells to sublethal
external stimuli such as soaking them in the acidic medium, a
method that entirely forgoes the introduction of transcription
factors [26] —though the veracity of this paper is called into
question at this moment, and even if it turned out to be a real
phenomenon, it is yet to be ascertained whether this stress-
triggering method can be applicable to older adults who suffer
from diseases and whether the reprogrammed cells do not gain
tumorigenic potential.
With these new advances at hand, the Japanese investiga-
tors conducting the iPSC-derived RPE transplant study have
adopted one of such non-integrative reprogramming methods,
using episomal Epstein-Barr virus (EBV) vectors that carry
plasmids encoding transcription factors without one of onco-
genic transgenes, c-Myc [27, 28]. They have also elaborated
the procedure to purify iPSC-derived RPE cells by carefully
selecting developed hexagon-shaped brown pigmental cells.
They also created RPE sheets by putting isolated RPE cells
together, so that those cells remain as stable and less likely to
transform as possible. In addition, these researchers diligently
conducted first through fourth animal tumorigenicity tests
over the past 2 years, using over a hundred mice and several
macaque monkeys and reported that none of them actually
developed tumors after iPSC-derived RPE transplant [27].
(For measures taken by the investigators to reduce research-
associated risks, see Table 1.)
However, we need to recognize that, regardless of which
method to establish iPSCs is used, those artificially
reprogrammed pluripotent cells are cells that have risks for
tumorigenicity. Even if c-Myc and other oncogenic genes
were all replaced by other transcription factors, successful
creation of pluripotent stem cells should, by definition, ac-
company secondary activations of proto-oncogenes including
c-Myc. Moreover, when plasmid vectors are used to produce
iPSCs, we should note that a small percentage of plasmids are
known to actually integrate into the chromosomes of a few
host cells [21, 29]. This occasional integration issue may be
surmountable, for PCR- based analysis can detect all the
integration sites [30], and researchers will at least be able to
inspect the established iPSCs and select integration-free
clones for clinical applications. Nevertheless, genomic inte-
gration is not the only problem related to tumorigenicity. EB
virus infection-associated cellular inflammation and
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subsequent genomic instability can also cause tumors that are
unrelated to genomic insertion. To be noted here is that the use
of EBV-based episomal plasmid vector requires simultaneous
use of supportive genes or elements (woodchuck hepatitis
post-transcriptional regulatory element, or WPRE, and the
EBV nuclear antigen 1 gene, or EBNA1) that are associated
with oncogenic potential [31, 32]. As for such inevitable
genomic instability, the Japan’s research panel in the Ministry
of Health, Labor and Welfare advised the iPSC-RPE clinical
investigators to conduct whole genome sequencing, exome
sequencing and CNV analysis on the first several iPSC lines,
and the investigators agreed to do so [27]. These analyses will
provide us with useful generalizable knowledge about the
genomic instability and tumorigenic potential of iPSC-
derived cells, but they are not meant to reduce the tumorige-
nicity risks for the participating patients. There are alternate
integration-free reprogramming methods other than the use of
EBV-based vectors, such as the RNA- or chemical compound-
mediated reprogramming mentioned above, which could
eventually turn out to be safer. However, it will take months
to test the clinical applicability of those new methods. Wheth-
er patients should wait until another reprogramming method is
fully developed and clinically applied, or whether it is advis-
able to go ahead to join the pilot study with the current
protocol, would be a meaningful ethical question to discuss.
As for the seemingly favorable preclinical animal tests, we
should keep in mind that all the mice used in the study were
observed for three to six months before being sacrificed, and
Table 1 Concerns and countermeasures
(A) Types of Concern (B) Measures Taken (C) Counterarguments
Tumorigenicity Use of viral vectors that integrate








plasmids, which remain in the host
cell for 10–14 days for the cell-
reprogramming purpose but





■ Undeniable chance of integration of
a small percentage of plasmids into
host genome
■ Oncogenic potential of wile-type
woodchuck hepatitis post-
transcriptional regulatory element
(WPRE), a fragment encoded in the
plasmid to facilitate strong
expression of reprogramming
genes
■ Possible cell proliferation
encouraged by the EBV nuclear
antigen 1 (EBNA1) gene, which is
indispensable for temporal
bindings of plasmids to the host
chromosomes
■ Tumorigenicity risks unrelated to
genomic insertion being
unresolved
Use of oncogenic transcription genes To substitute c-Myc with alternative
factors
Malignant transformation of residual
undifferentiated cells
To purify RPE cells to eliminate
undifferentiated low-grade cells; to
conduct product inspection
Reactivation of tumorigenic network
in differentiated RPE cells
To create an RPE sheet so that the
differentiated cells remain stable
and hard to transform
Immunosuppression encouraging
tumor formation
Autologous transplant that may
reduce the risk of immune rejection
■ Fundamental question about
inherent tumorigenic potential of
iPSCs
■ Possibility of contamination not
being ruled out
■ Possibility of de-differentiation of
injected cells into tumorigenic
immature cells due to
microenvironment in vivo
■ Limited data of macaque monkeys
at presentLikelihood and degree of
immune rejection yet to be
investigated
Graft survival Immune rejection Same as above Same as above
Low-efficiency in survival of graft
cells
■ The more differentiated, the harder
the graft cells tend to survive in vivo
Others Risks associated with eye surgery
(retinal detachment, etc.)
Viral infection caused by
contaminated graft cells
Manufacture in compliance of Good
Manufacturing Practice
Others
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the survival of the autologous RPE-transplanted macaque
monkey was observed for only 1 year. Thus, long-term tu-
morigenicity of the transplanted cells in humans has yet to be
ascertained. Over time, the microenvironment for injected
cells in situ could result in late-onset tumorigenic events.
There is a reasonable possibility that the aforementioned
non-integrative, non-retroviral cell reprogramming method
will only postpone the onset of tumorigenesis, rather than
eliminate the tumorigenic potential of the iPSCs.
Granted that the research subjects will be carefully moni-
tored for 1 year with a subsequent three-year follow-up, some
patients may understand and accept the risks of tumorigenicity
in the hope that this novel treatment strategy will give them
sufficient therapeutic benefits. Other patients may think, how-
ever, that those are potentially life-threatening risks that are
completely avoidable by not participating in the current re-
search project. In response to the seemingly alarmist descrip-
tion of the tumorigenicity risks of iPSCs presented above,
researchers may explain to patients that, in worst case scenar-
ios, one can always remove the eye if there are any localized
adverse events related to the cell transplant, and that this is
exactly one of the reasons why an eye disease was selected for
the first-in-human iPSC-based transplant study. However,
given the fact that many wet AMD patients continue to
maintain peripheral vision of 20/400 and above (as discussed
below), some patients would reasonably prefer a 100 %
chance of having their minimum vision over a small chance
of losing one eye, unless they can expect that the transplant
will bring them extra benefits. Our next question is whether
these risks can be outweighed by potential therapeutic
benefits.
Potential Benefits?
For patients, any potential benefits of clinical research may be
worth pursuing when they can expect that the chance of
obtaining such benefits exceeds the benefits from existing
treatment or non-treatment options, without suffering from
major side effects.
AMD is not a fatal disease, but it affects patient’s quality of
life by impacting one’s central vision. According to American
Macular Degeneration Foundation, the likely scenario for wet
AMD patients would be a life with visual acuity gradually
falling down to somewhere between 20/80 and 20/400, but in
some cases it could be worse [33].
Current treatment options for wet AMD include (1) month-
ly anti-VEGF (vascular endothelial growth factor) injections
into the eye to block the growth of CNVs and (2) photody-
namic therapy or laser surgery to halt the growth of CNVs.
However, these are not cures, and the patient’s condition could
get worse even with treatment. The National Eye Institute’s
Age-Related Eye Disease Study (AREDS) found that (3) the
intake of a particular combination of antioxidants and zinc
could reduce the risk of worsening the patients’ AMD condi-
tion to a certain degree [34]. Despite these attempts, it is true
that more effective therapies that can restore vision are antic-
ipated. In February 2013, FDA approved the Argus II Retinal
Prosthesis System, an implanted retinal prosthesis (artificial
retina) connected to a small video camera and a video pro-
cessing unit [35], but this approach requires invasive surgery
and unwieldy equipment. This is why various cell therapies
are being attempted intensively.
Then how much improvement can AMD patients expect
with cell therapy? An example closest to the iPSC-RPE trans-
plant would be ESC-derived RPE transplant for macular de-
generation in animal models and in a few patients. Putting
ethical controversies on the clinical use of ESC-derived cells
aside, we can at least predict regenerative medicine’s thera-
peutic effects on a patient’s vision.
In animal studies, transplantation of primate ESC-derived
RPE cells into 4-week-old Royal College of Surgeons (RCS)
rats, a widely accepted rodent model of AMD, has reportedly
enhanced the survival of the rats’ photoreceptors and im-
proved the visual function [36]. This functional improvement
was interpreted by the rats’ frequent head-tracking behavior
while watching a rotating black-and-white stripe cylinder
8 weeks after transplantation. Another group reported similar
results [37, 38]. This can be seen as a promising sign of
effectiveness of the transplant, but these results need to be
cautiously interpreted. Using head tracking in rats as readout
of evaluation of visual acuity may not be reliable indication of
visual function in humans. We should also note that the ages
of tested rats do not match the patient population of AMD, for
it is obvious that younger mammals can adapt therapeutic
benefits more successfully than older mammals. Lastly, in
most, if not all, of these studies, scientists use “sham” as
control. However, a more appropriate control should be some
cells without regenerative capacity, or ideally, cells used in
previous clinical trials such as fetal-eye-derived RPE
transplant.
In human cases, there are two clinical trials using distinct
cells for transplantation, human ESC-derived RPE cells and
human-fetal-eye-derived RPE cells, which showed mixed re-
sults for AMD patients. The first trial with human ESC-
derived RPE cells is still on-going, and has been done with
only two patients, one with dry AMD and the other with
Stargardt’s, a juvenile macular dystrophy [39]. Outcome for
a patient with Stargardt’s has been somewhat encouraging,
whereas that for a patient with AMD has been mediocre. On a
positive note, although the follow-upwas as short as 4months,
both patients showed no sign of tumorigenicity or of immune
rejection of the grafts. Following the moderate improvement
of the dry AMD patient’s best corrected visual acuity from 21
to 33 letters on the ETDRS chart (Fig. 3, improvement from
20/500 to 20/200) at week 2, it gradually worsened to reading
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28 ETDRS letters (20/320) by week 6. Authors claim that the
possible reason for this limited improvement is due to the
patient’s failure to follow the immunosuppressive regimen
for the first week after transplant.
The other trial of human-fetal-eye-derived RPE transplant
may endorse the concern that the visual improvement gained
can be temporary [40]. In this phase II trial, 7 out of 10 patients
(including all 4 dry AMD patients involved) showed im-
proved EDTRS visual acuity scores without showing the sign
of graft rejection. Interestingly, there is one case in which a
patient (with retinitis pigmentosa, not AMD) showed remark-
able visual improvement from seeing nothing but shadows
(20/800) to reading large prints and sending emails (20/160)
within a year, but even in this case, her visual acuity started to
deteriorate after a couple of years and it had dropped down to
20/320 after 6 years. Authors suggest that this temporary
visual improvement may not be ascribed to the successful
functioning of the transplanted RPE cells, but to the “trophic
effect” in which the graft is releasing growth factors to help
restore deteriorating host photoreceptors [40, 41]. If this ex-
planation is true, would it not be equally effective and less
invasive to directly inject these growth factors into the
subretinal spaces of patients’ eyes, rather than to let patients
undergo transplant surgery? In any case, sample sizes of these
studies were still limited, and further studies are needed to
determine the therapeutic efficacy of these replacement
therapies.
The inclusion criteria of Japan’s iPSC-RPE clinical re-
search specifies that the qualified patient’s vision should be
as wrong as hand motion to 20/67 (0.3 in decimals) and that a
patient must have tried the standard wet AMD treatment – at
lest four times of anti-VEGF injection treatment – but failed
[42]. Given the results of the previous clinical trials, those
patients who currently have vision better than the expected
from these trials would wish to reexamine the meaning of
joining the study. One last point that might be worth consid-
ering is that it remains unclear whether and how the iPSC-
derived RPE transplant would prevent the neovascularization
in the wet AMD patient’s eye and the relapse of the disease.
Patients should be aware that the RIKEN’s informed consent
document clearly states that such a relapse, or the non-efficacy
of the transplant, will not be regarded as “health damage” and
hence will not be compensated by the RIKEN and the collab-
orating hospital.
Getting back to the potential benefits alluded in the in-
formed consent document of the Japan’s clinical study, we
propose that the experimental nature of the study and the
uncertainty of its therapeutic benefits should be conveyed to
participating patients more clearly. When possible therapeutic
benefits, such as the improved brightness in the central vision
or the improved visual acuity, are mentioned during the in-
formed consent process, researchers and recruiting physicians
should give interested patients perspicuous explanations of
whether those favorable effects are the direct results of the
use of iPSCs or whether the same effects can be caused by any
surgery to remove the developed CNVs or by the simple
injection of growth factors. Such an articulation would be
more ethically appropriate because it will allow patients to
carefully compare effects and risks of alternative studies and
therapies. Given the excitement and hypes about iPSC re-
search among the Japanese people and the media, a slightly
wary explanation of the study may be rather useful for a
patient to make a considered decision.
Conclusion
At times, humans tend to be goal-oriented, and when one
realizes the decline in one’s health a fight for recovery is not
uncommon. A patient’s desperation can be easily exploited for
purposes unrelated to their future well-being. Researchers
should be aware of this tendency when alluding to potential
benefits.
Some patients may still have reasons to participate in iPSC-
based transplant study at this point in time. If one were a
patient who aspires to stop the progress of his eye disease
now to accomplish tasks that were otherwise impossible on
his own, or if one were an elderly patient genuinely wishing to
make a small piece of contribution to future medicine at the
final stage of his life, one may be ready to undertake the
presumably small chances of research-associated risks. Others
may simply decide not to participate in research. It is up to
individuals. Before they make up their minds, however, re-
search risks and possible benefits have to be examined from
various viewpoints and compared with other options. Prior to
participation in the study, prospective participants should also
be given the opportunity to observe how other AMD patients
cope with, or have even overcome, their hardships with
Fig. 3 ETDRS Chart (Credit: National Eye Institute, National Institutes
of Health) is used to detect subtle changes in a low-vision patient’s visual
acuity
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various non-therapeutic devices and supports. With or without
effective therapies, AMD patients should not live in social
isolation without various activities and communications they
used to embrace.
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